Clinical Trials
3 trialsNCT03460977 2026-06-05
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
Phase 1 Recruiting
NCT06629779 2026-06-05
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer
Phase 3 Recruiting
NCT07028853 2026-06-05
MEVPRO-3
Pfizer
Phase 3 Recruiting